Table. 1.

Table. 1. Table 1

IBS-related disease: characteristics of selected clinical trials included in the review

Reference	Type of study	Clinical setting/population	Sample size	Age (year)	Daily dose	Probiotic species	Duration of intervention	System	Main outcomes
El-Salhy et al., 2020 (Norway)	RCT	IBS	165	39.9±9.0	30 g FMT or 60 g FMT at a ratio of 1:1:1 The material for FMT	FMT	3 months	IBS-QoL	Positive effect
Catinean et al., 2019 (Romania)	RCT	IBS	90	18-75 G1=38.77±10.96 G2=39.07±16.00 G3=40.37±11.95	G2=7 days: 1 cap 27 days: 2 cap	G1=Bifidobacterium longum W11 G2=five Bacillus spp.	34 days G1 and G3=10+24 G2=34	IBS-QoL (SF-36)	Positive effect
Preston et al., 2018 (USA)	RCT	IBS	86	Plac: 39.9 Int: 40.6	2 capsules 50×10⁹ CFU	Lactobacillus acidophilus CL1285, L. casei LBC80R, and L. rhamnosus CLR2	12 weeks	IBS-QoL	Positive effect
Giannetti et al., 2017 (Italy)	RCT	Children with IBS and functional dyspepsia	73	8.0-17.9	3 billion (3×10⁹) of Bifidobacterium longum BB536, 1 billion (1×10⁹) of B. infantis M-63, 1 billion (1×10⁹) of B. breve M-16V	3 Bifidobacteria:M-63breve M-16Vlongum BB536	16 weeks: 2-week run-in phase 6 weeks Int 2-week “washout” Afterward, each patient was switched to the other group 6 weeks Int	FDI	Positive effect
Pinto-Sanchez et al., 2017 (Canada)	RCT	IBS	44	Int: 46.5 (30-58) Plac: 40.0 (26-57)	1.0E+10	Bifidobacterium longum NCC3001 (BL)	6-week treatment 10 week follow-up	SF-36	Positive effect
Nobutani et al., 2017 (Japan)	RCT	IBS	30	Int: 52.6±20.1 Plac: 45.9±19.5	13×10⁸ CFU	Lactobacillus gasseri CP2305	4 weeks	IBS-QoL and PSQI-J	Positive effect
Choi et al., 2015 (Korea)	RCT	Non-diarrheal-type IBS	285	20-73 (47)	Group 1: 1.0×10¹⁰ CFU Groups 2 and 3: 1.5×10¹⁰ Group 4: 3×10¹⁰	Bacillus subtilis and Streptococcus faecium	4 weeks	IBS-QoL	Positive effect
Abbas et al., 2014 (Pakistan)	RCT	IBS-D	72 64 (completed)	18-60 Int: 37.7±11.6 Plac: 33.0±12.0	750 mg/d	Saccharomyces boulardii	2-week run-in 6 weeks Int	IBS-QoL	Positive effect
Lorenzo-Zúñiga et al., 2014 (Spain)	RCT	IBS	73	20-70 Int: 47.5±13.1 46.3±11.6 Plac: 46.5±13.1	1-3×10¹⁰ CFU or 3-6×10⁹	Two Lactobacillus plantarum (CECT7484 and CECT7485) and one Pediococcus acidilactici (CECT7483)	6 weeks	IBS-QoL	Positive effect
Cappello et al., 2013 (Italy)	RCT	IBS	64	38.7±12.6	5×10⁹ Lactobacillus plantarum, 2×10⁹ L. casei subp. rhamnosus and 2×10⁹ L. gasseri, 1×10⁹ Bifidobacterium infantis and 1×10⁹ B. longum, 1×10⁹ L. acidophilus, 1×10⁹ L. salivarius and 1×10⁹ L. sporogenes and 5×10⁹ Streptococcus thermophilus Prebiotic inulin 2.2 g	Lyophilized bacteria: L. plantarumL. casei subp. rhamnosusL. gasseriBifidobacterium infantisL. acidophilusL. salivariusL. sporogenesStreptococcus thermophilus Prebiotic inulin	6 weeks (2-week run-in and 4-week treatment)	SF-36	Positive effect
Choi et al., 2011 (Korea)	RCT	IBS	67	41±13	2×10¹¹	Saccharomyces boulardii	4 weeks	IBS-QoL	Positive effect
Drisko et al., 2006 (USA)	Open-label pilot study Prospective outcome study	IBS	20	24-81	10 billion CFU	Lactobacillus acidophilus, Bifidobacterium bifidum, L. rhamnosus, L. plantarum, B. infantis, L. salivarius, L. bulgaricus, L. casei, L. brevis, and Streptococcus thermophilus	1 year	IBS-QoL	Positive effect

RCT, randomized control trial; IBS, irritable bowel syndrome; FMT, fecal microbiota transplantation; QoL, quality of life; IBS-QoL, irritable bowel syndrome QoL; IBS-D, diarrhea-dominant irritable bowel syndrome; SF-36, 36-item short form survey; CFU, colony forming unit; FDI, Functional Disability Inventory; Int, intervention; Plac, placebo; PSQI-J, Pittsburgh Sleep Quality Index.

Prev Nutr Food Sci 2024;29:237~255 https://doi.org/10.3746/pnf.2024.29.3.237